Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rabeprazole vs Pantoprazole for Nocturnal Acid Secretion in GERD
NCT00304421Phase 4Completed
- Sponsor
- VA Greater Los Angeles Healthcare System
- Start
- Jan 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of rabeprazole in gastroesophageal reflux disease (GERD) (2 arms), sponsored by VA Greater Los Angeles Healthcare System. Primary endpoint: Change from baseline in gastric acid secretion. Started Jan 2004; status: completed.
02
Drugs
rabeprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT00304421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00304421.